DT07 Rec'd PCT/PTO 0 4 MAR 2005

CASE 4-32444A

EV524615020115
Express Mail Label Number

EV524615020115
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF COPPOLA ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP 03/03466

FILED: 2 APRIL 2003

U.S. APPLICATION NO: 10/510,026

35 USC §371 DATE:

FOR: 5-SUBSTITUTED 1,1-DIOXO-1,2,5-THIADIAZOLIDIN-3-ONE

DERIVATIVES

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.



The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Paivi Kukkola

Reg. No. 50,499

Agent for Applicants

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7875

Date: Harch 4, 2005

-2-

FORM PTO-1449 (REV. 7-85)

EXAMINER

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-32444A APPLICATION NO. 10/510,026 APPLICANT COPPOLA ET AL. FILING DATE **OCTOBER 1, 2004**

Group

U.S. PATENT DOCUMENTS

			DATE NAME		CLASS	SUBCLASS	FILING DATE	
EXAMINER INITIAL		DOCUMENT NUMBER			514	364	4/16/97	
.	AA	5,958,957	9/28/99	Anderson et al.			2/19/99	
	AB	5,972,978	10/26/99	Anderson et al.	514	361	<u> </u>	
		6,063,800	5/16/00	Anderson et al.	514	369	2/19/99	
	AC.		6/27/00	Anderson et al.	514	359	2/19/99	
	AD	6,080,770			514	309	5/10/91	
	AE	5,162,340	11/10/92	Chakravarty et al.				
	AF	5,281,614	1/25/94	Ashton et al.	514	359	11/2/92	
			5/2/95	Chakravarty et al.	546	118	9/2/92	
	AG	5,412,097			514	361	2/19/99	
	ΑH	5,972,978	10/26/99	Andersen et al.	1514	 		
	Al						<u> </u>	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	+	WO 97/40017	10/30/97	PCT				
*	AJ AK	WO 01/19831	3/22/01	PCT				
*	AL	0 512 870	11/11/92	EP				
	AM	WO 92/20687	11/26/92	PCT				
	AN	110 0223001						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

		1 2 1/2 1 1 1 1 1 1 1 1 1
	AO	Albericio et al., "Synthesis of a Sulfahydantoin Library", J. Comb. Chem. Vol. 3, pp 290-300 (2001)
		Bright et al., "Competitive particle concentration fluorescence immunoassays for measuring
*	AP	antidiabetic drug levels in mouse plasma" Journal of Immunological Metriods, vol. 207, pages
		Abstract , Eberle et al., "Preparation of microbiocidal N-phenyl-N [4- (-pyridyl)-pyrimidin-2-yl) amines
	AQ	
	AR	Ducry et al., "Synthesis of 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide Derivatives and evaluation of their affinity for MHC Class-II Proteins", Helvetica Chimica, Acta, Vol. 82, No. 12, pp. 2432-2447 (1999)
		Mantegani et al., "Synthesis and Antihypertensive Activity of 2,4-dioxoimidazolidin-1yl and perhydro-
ŧ	AS	2,4-dioxopyrimidin-1-yl ergoline derivatives", IL FARMACO, vol. 53, pp 293-304 (1998)
EVAN	IIII	DATE CONSIDERED

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in *EXAMINER: conformance and not considered. Include a copy of this form with the next communication to applicant.